N-acetylcysteine and NMDA Antagonist Interactions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00611897|
Recruitment Status : Completed
First Posted : February 11, 2008
Results First Posted : May 8, 2015
Last Update Posted : May 8, 2015
|Study Design||Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor)|
Drug: N-acetylcysteine and ketamine
Drug: placebo and ketamine
The study was approved by the institutional review boards of Yale Medical School and the Veterans Administration Connecticut Healthcare System. Healthy volunteers were recruited by advertisements.
as determined by Structured Clinical Interview for DSM-IV, Non-Patient Edition.
|Pre-assignment Details||All subjects gave written informed consent. They had no personal or family history of psychiatric or substance abuse disorders. A total of 43 subjects consented; 21 of them never initiated the study due to ineligibility or scheduling conflicts, and 6 subjects dropped out. Sixteen subjects completed the study procedures.|